Roza Seidakhmetova

Prof. Roza Seidakhmetova


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2026 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
ZNZhangeldy Nurmaganbetov
Zhangeldy Nurmaganbetov
RSRoza Seidakhmetova
Roza Seidakhmetova
ИИИТЖАНОВА ИСКОЖИЕВНА
ИТЖАНОВА ИСКОЖИЕВНА
PBPernesh Bekisheva
Pernesh Bekisheva
АКАйкоркем Кызкенова
Айкоркем Кызкенова
The antiviral activity of compound (5) was demonstrated by a reduction in influenza A viral infectivity of 2.0 log10 for H3N2 (99% inactivation) and 1.9 log10 for H1N1 (98.7% inactivation) at a dose of 0.4 mg/embryo. The compound demonstrated no noticeable embryotoxicity at the maximum tested dose of 0.4 mg/embryo, while the LD50 was not reached within the investigated concentration range. Notably, its therapeutic index outperforms rimantadine and oseltamivir. Furthermore, a scalable 8-stage laboratory production protocol was successfully validated. These findings position compound (5) as a highly promising, low-toxicity domestic prototype for the development of innovative, multi-targeted anti-influenza pharmaceutical drugs.